Eriksen JG - Search Results

1

Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.

Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR; Danish Head and Neck Cancer Study Group. Overgaard J, et al. Among authors: eriksen jg. Lancet Oncol. 2005 Oct;6(10):757-64. doi: 10.1016/S1470-2045(05)70292-8. Epub 2005 Aug 27. Lancet Oncol. 2005. PMID: 16198981 Clinical Trial.

2

Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck.

Overgaard J, Alsner J, Eriksen J, Horsman MR, Grau C. Overgaard J, et al. Rays. 2000 Jul-Sep;25(3):313-9. Rays. 2000. PMID: 11367896 Review.

3

The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck.

Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. Eriksen JG, et al. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):561-6. doi: 10.1016/j.ijrobp.2003.09.043. Int J Radiat Oncol Biol Phys. 2004. PMID: 14751528

4

Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas.

Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Eriksen JG, et al. Radiother Oncol. 2004 Sep;72(3):275-82. doi: 10.1016/j.radonc.2004.07.014. Radiother Oncol. 2004. PMID: 15450725 Clinical Trial.

5

Expression of integrins and E-cadherin in squamous cell carcinomas of the head and neck.

Eriksen JG, Steiniche T, Søgaard H, Overgaard J. Eriksen JG, et al. APMIS. 2004 Sep;112(9):560-8. doi: 10.1111/j.1600-0463.2004.apm1120902.x. APMIS. 2004. PMID: 15601304

6

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study.

Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer study group (DAHANCA). Eriksen JG, et al. Radiother Oncol. 2005 Feb;74(2):93-100. doi: 10.1016/j.radonc.2004.12.018. Radiother Oncol. 2005. PMID: 15816106 Clinical Trial.

7

The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma.

Eriksen JG, Steiniche T, Overgaard J; Danish Head and Neck Cancer study group (DAHANCA). Eriksen JG, et al. Acta Oncol. 2005;44(1):50-8. doi: 10.1080/02841860510007396. Acta Oncol. 2005. PMID: 15848906 Clinical Trial.

8

The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times.

Eriksen JG, Alsner J, Steiniche T, Overgaard J. Eriksen JG, et al. Radiother Oncol. 2005 Aug;76(2):135-42. doi: 10.1016/j.radonc.2005.05.004. Radiother Oncol. 2005. PMID: 16024113

9

Tumour hypoxia - a characteristic feature with a complex molecular background.

Eriksen JG, Horsman MR. Eriksen JG, et al. Radiother Oncol. 2006 Nov;81(2):119-21. doi: 10.1016/j.radonc.2006.09.005. Epub 2006 Oct 16. Radiother Oncol. 2006. PMID: 17050018 No abstract available.

10

Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.

Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J. Nordsmark M, et al. Among authors: eriksen jg. Radiother Oncol. 2007 Jun;83(3):389-97. doi: 10.1016/j.radonc.2007.04.021. Epub 2007 May 17. Radiother Oncol. 2007. PMID: 17499868 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page